# A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor

> **NCT06239298** · PHASE1,PHASE2 · RECRUITING · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 130 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** ZG005 Powder for Injection
- **DRUG:** Donafenib Tosilate Tablets

## Key facts

- **NCT ID:** NCT06239298
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-10
- **Primary completion:** 2026-03
- **Final completion:** 2026-05
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2024-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06239298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06239298, "A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT06239298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*